EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix

Francesco Borriello iD, Gavin C K W Koh, Iñaki F Troconiz iD, Rounak Nassirpour, Lovely Goyal, Anvar Suyundikov, Akber Safder iD, Nicholas Robertson, Anna Allen, Andrew Robertson, Stephanie Straley, Pam Farmer und 7 weitere

The Journal of Infectious Diseases · 16.11.2026 · 234 (5) · 747-757

DOI: 10.1093/infdis/jiag349 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 14.07.2026. Verfasst von Francesco Borriello und 18 weiteren Autor:innen. Beteiligte Einrichtung: Generate:Biomedicines, Somerville, Massachusetts, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, Antibodies, Monoclonal, COVID-19 Drug Treatment. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Generate Biomedicines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antibodies against the SARS-CoV-2 spike receptor-binding domain provided effective COVID-19 treatment until resistant variants emerged. GB-0669 is a half-life–extended monoclonal antibody optimized using artificial intelligence. It targets the conserved spike S2 stem helix, a region subject to limited selective pressure from antibody responses induced by natural infection or vaccination.

Methods

Preclinical safety studies were conducted in cynomolgus monkeys. In the first-in-human trial, healthy adults aged 18–55 received single intravenous doses of GB-0669 or placebo in 5 ascending cohorts (100, 300, 600, 1200, and 2400 mg). Participants were monitored for 43 weeks to evaluate safety, pharmacokinetics (PK), and pharmacodynamics (PD; serum live virus neutralization). In vitro studies assessed neutralization of GB-0669 combined with antiviral drugs (remdesivir, nirmatrelvir, and molnupiravir).

Results

Preclinical studies revealed no safety concerns. In the clinical trial (n = 51; 36 GB-0669, 15 placebo), GB-0669 was well-tolerated without dose-limiting toxicities; all adverse reactions were mild (Grade 1 or 2). Pharmacokinetics showed dose proportionality up to 2400 mg, with a half-life of 54 days. Dose-dependent increases in serum live virus neutralization occurred at 600 and 1200 mg, with separation from placebo. The estimated neutralizing index that adjusts GB-0669 serum concentrations for its in vitro neutralizing potency supported therapeutic efficacy for 2 weeks post-administration. Finally, in vitro experiments showed improved neutralization profiles of GB-0669 in combination with antivirals.

Conclusions

The data support exploring GB-0669 at 1200 mg in a Phase 2 trial for treating COVID-19 in immunocompromised individuals. The combination of GB-0669 with antiviral drugs may offer additional therapeutic benefits. Clinical Trials Registration ClinicalTrials.gov Identifier. NCT07050511.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, MonoclonalCOVID-19 Drug TreatmentAntibodies, ViralHumansAdultAnimalsDouble-Blind MethodMiddle AgedMacaca fascicularisMaleFemaleYoung AdultAdolescentAntibodies, NeutralizingAntiviral AgentsCOVID-19Antibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Phase 1 clinical trialSARS-CoV-2artificial intelligence/machine learningfirst-in-classmonoclonal antibody therapy

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodies, MonoclonalAntibodies, ViralAntibodies, NeutralizingAntiviral AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Generate:Biomedicines, Somerville, Massachusetts, USA.
  • Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
  • IdisNA, Navarra Institute for Health Research, Pamplona, Spain.
  • Institute of Data Science and Artificial Intelligence, DATAI, University of Navarra, Pamplona, Spain.
  • PPD, Orlando, Florida, USA.
  • San Francisco, California, USA.

ORCID-Profile: Francesco Borriello, Iñaki F Troconiz, Akber Safder, Amarendra Pegu

Förderung

  • Generate Biomedicines

Zitieren

APA

Borriello, F., Koh, G. C. K. W., Troconiz, I. F., Nassirpour, R., Goyal, L., Suyundikov, A., Safder, A., Robertson, N., Allen, A., Robertson, A., Straley, S., Farmer, P., Murphy, D., Carlin, E., Schmitt, K. P., Pegu, A., Hazuda, D., Snyder, A., & De Alwis, D. P. (2026). Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. The Journal of Infectious Diseases, 234(5), 747-757. https://doi.org/10.1093/infdis/jiag349

Vancouver

Borriello F, Koh GCKW, Troconiz IF, Nassirpour R, Goyal L, Suyundikov A, et al. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix. The Journal of Infectious Diseases. 2026;234(5):747-757. doi:10.1093/infdis/jiag349

BibTeX
@article{Borriello2026,
  author = {Borriello, Francesco and Koh, Gavin C K W and Troconiz, Iñaki F and Nassirpour, Rounak and Goyal, Lovely and Suyundikov, Anvar and Safder, Akber and Robertson, Nicholas and Allen, Anna and Robertson, Andrew and Straley, Stephanie and Farmer, Pam and Murphy, Denise and Carlin, Eric and Schmitt, Kimberly P and Pegu, Amarendra and Hazuda, Daria and Snyder, Alexandra and De Alwis, Dinesh P},
  title = {Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {234},
  number = {5},
  pages = {747--757},
  doi = {10.1093/infdis/jiag349}
}
Kostenlos starten →